Safety and effectiveness of GLP-1 receptor agonists and SGLT-2 inhibitors in liver transplant recipients with diabetes - 19/08/26
, Philippe Sultanik a, Aida Rebiha a, Raluca Pais a, Dominique Thabut a, b, Olivier Scatton b, c, Olivier Bourron d, e, 1, Filomena Conti a, 1Highlight |
• | Available data on GLP-1 RAs and SGLT-2 inhibitors use in LT recipients are limited. |
• | 90.0% of LT recipients with diabetes achieved HbA1c target with GLP-1RA/SGLT2i. |
• | Treatment was well tolerated, with moderate adverse events reported in 15.0% of patients. |
• | Gastrointestinal disorders occur in 8.5% of patients. |
Abstract |
Background |
We studied the safety and effectiveness of glucagon-like peptide-1 receptor agonists (GLP1-RAs) and sodium-glucose co-transporter-2 inhibitors (SGLT2is) in liver transplant recipients with diabetes.
Methods |
This retrospective single-center study included 41 patients treated with GLP1-RAs and/or SGLT2is after liver transplantation (LT) who were compared to a control group receiving antidiabetic treatment excluding GLP1-RAs and/ SGLT2is.
Results |
The treatment group showed no serious adverse events, with 15.0% experiencing moderate side effects, primarily gastrointestinal disorders. The HbA1c target concentration was achieved in 90.0% (n=36) of patients in the GLP1-RA and/or SGLT2i group versus 74.0% (n = 42) in the control-group ( p = 0.16). The fasting glycaemia target was reached by a higher proportion of patients in the GLP1-RA and/or SGLT2i group than in the control-group: 80.0% versus 55.0%, p = 0.033. Insulin withdrawal was greater in the group of patients receiving GLP1-RAs and/or SGLT2is treatment, in particular for those with post-transplant diabetes (80.0% vs. 0%, p < 0.01). The median time of follow-up was 11.0 months (IQR: 6-13).
Conclusions |
Our results suggest the safety of GLP1-RAs and SGLT2is treatment, with the remarkable benefit of insulin withdrawal for a subgroup of patients with new-onset diabetes. However, larger prospective studies are needed to assess the long-term impact on cardiovascular events, obesity, liver steatosis, and mortality.
Le texte complet de cet article est disponible en PDF.Keywords : New-onset diabetes, Glucagon-like peptide-1 receptor agonists, Sodium-glucose co-transporter-2 inhibitors, Glycemic control, Insulin withdrawal
Plan
Vol 50 - N° 8
Article 102899- octobre 2026 Retour au numéro
Article précédent
- Efficacy and safety of empagliflozin in metabolic dysfunction–associated steatotic liver disease: A systematic review and meta-analysis
- Shambo Samrat Samajdar, Shashank R Joshi, Gaurab Bhaduri, Banshi Saboo, Krishnendu Roy, Shatavisa Mukherjee, Snehal Bansode, Sanjay Bandyopadhyay
- Management of portal vein thrombosis in cirrhosis: Risks, treatments, and outcomes of a retrospective multicenter study with over 10 years of follow-up
- Ting Jiang, Xue-ping Cui, Yue-shan Yin, Dan-qing Xu, Ju-yan Chen, Li-hong Yang, Hong-tao Lei, Yuan-xi Jian, Ben Niu, Jin-hui Yang
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?